LATEST NEWS

The IVA-100 list is a yearly list that recognizes top research in Sweden with high scientific value and commercial potential.

​

This study presents the learning outcomes from over two-year long monitoring of SARS-CoV-2 in Stockholm, Sweden, where hpPCR was used as proof-of-concept for variant profiling.

APLEX Bio will be pitching the international investor community at Nordic Life Science Days in Malmö, Sweden alongside 39 other startups.

APLEX Bio announces it has demonstrated superior performance of multiplexed COVID variant detection in wastewater, including the generally difficult to detect variant BA.2, using its next-generation hpPCR technology. In a study where samples were tracing back to the end of 2021, results showed that BA.2 could be detected at least one week and up to three weeks earlier compared to next-generation sequencing (NGS) analysis. The study also demonstrated how APLEX Bio’s hpPCR enables ultra-sensitivite analysis while retaining specificity with a cost-effective and rapid workflow going from sample to result within 3 hours.

Sweden's Aplex Bio Gearing up to Launch 'Hyperplexed' PCR Platform

APLEX Bio announces it has raised 14 MSEK (€1.3M) for developing its massive multiplexing technology that enables detection of more than 100 biomolecules (DNA, RNA, proteins) with single molecule sensitivity in each drop of sample, without the need for sequencing or other complex instrumentation.

APLEX Bio develops breakthrough massive multiplexing technology that enables detection of more than 100 biomolecules (DNA, RNA, proteins) with single molecule sensitivity in each drop of sample, without the need for sequencing or other complex instrumentation.